Regulation & Industry news
Regulation & Industry
Novartis will work with a US biotech company on new cancer therapies, while Lilly has partnered with a Chinese biopharma firm to develop new medicines. 25 June 2026
Regulation & Industry
Weight loss drugs promise a diabetes breakthrough in Africa, but patent barriers stall access. What does COVID-19 tell us about how to solve the continent’s silent crisis? Asks Sofia Araújo of Inventa. 24 June 2026
Regulation & Industry
The partnership, announced at BIO 2026, marks the largest Asia-Pacific partnership by potential value that the AI-driven drug discovery company has secured to date. 22 June 2026
Regulation & Industry
Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study. 18 June 2026
Regulation & Industry
The post-grant challenge landscape is intensifying on both sides of the Atlantic. This panel analyses recent developments in IPRs, PGRs, EPO oppositions, and the UPC, detailing strategies to simultaneously defend existing portfolios and clear competitive space. 29 May 2026
Regulation & Industry
Structuring successful IP transactions in the life sciences sector requires rigorous due diligence and sophisticated valuation models. This panel brings together deal-makers and valuation experts to share strategies for protecting value and enabling innovation in complex M&A and licensing deals. 27 May 2026
Regulation & Industry
Are life sciences cases gaining momentum in the new Unified Patent Court? This session provides a critical update on the UPC's evolving jurisprudence, looking at emerging legal tests and the specific challenges of preliminary injunctions for life sciences products. 14 May 2026
Regulation & Industry
The science and technology conglomerate’s big diagnostics bet comes with monitoring technology, an AI-powered product pipeline, and a litigation history that has kept Silicon Valley’s biggest player on the back foot. 18 February 2026